LKPC(SH:600789) Xin Lang Cai Jing·2025-08-28 02:28Core Insights - Luantang Pharmaceutical (600789.SH) reported a total revenue of 3.154 billion yuan for the first half of 2025, ranking 18th among disclosed peers, which is a decrease of 125 million yuan or 3.83% year-on-year [1] - The net profit attributable to shareholders was 107 million yuan, ranking 47th among peers, down by 193 million yuan or 64.38% compared to the same period last year [1] - The net cash inflow from operating activities was 312 million yuan, ranking 24th among peers, an increase of 129 million yuan or 70.00% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 53.96%, ranking 107th among peers, a decrease of 0.69 percentage points from the previous quarter and 0.92 percentage points year-on-year [3] - The latest gross profit margin is 22.49%, ranking 108th among peers, an increase of 1.78 percentage points from the previous quarter and 0.04 percentage points year-on-year, marking three consecutive years of growth [3] - The latest return on equity (ROE) is 2.71%, ranking 64th among peers, a decrease of 5.08 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.12 yuan, ranking 64th among peers, a decrease of 0.21 yuan or 63.64% year-on-year [3] - The latest total asset turnover ratio is 0.35 times, ranking 14th among peers, a decrease of 0.02 times or 5.65% year-on-year [3] - The latest inventory turnover ratio is 1.78 times, ranking 28th among peers, a decrease of 0.15 times or 7.82% year-on-year [3] Shareholder Information - The number of shareholders is 124,100, with the top ten shareholders holding 258 million shares, accounting for 28.69% of the total share capital [3] - The largest shareholder is Hualu Holdings Group Co., Ltd. with a holding ratio of 20.69% [3]